Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Please use this identifier to cite or link to this item: https://dspace.uzhnu.edu.ua/jspui/handle/lib/2701

Full metadata record

DC Field	Value	Language
dc.contributor.author	Готько, Євген Степанович	-
dc.contributor.author	Peeters, Marc	-
dc.contributor.author	Jay Price, Timothy	-
dc.date.accessioned	2015-06-16T10:39:05Z	-
dc.date.available	2015-06-16T10:39:05Z	-
dc.date.issued	2010-11-01	-
dc.identifier.issn	0732-183X	-
dc.identifier.uri	https://dspace.uzhnu.edu.ua/jspui/handle/lib/2701	-
dc.description.abstract	Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status.	uk
dc.language.iso	en	uk
dc.publisher	JOURNAL OF CLINICAL ONCOLOGY	uk
dc.relation.ispartofseries	VOLUME 28;NUMBER 31	-
dc.subject	KRAS and Antibody Testing	uk
dc.subject	Panitumumab	uk
dc.subject	FOLFIRI	uk
dc.title	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer	uk
dc.type	Text	uk
dc.pubType	Стаття	uk
Appears in Collections:	Наукові публікації кафедри радіології та онкології

Files in This Item:

File	Description	Size	Format
JCO-2010-Peeters-4706-13.pdf	Основна стаття	366.8 kB	Adobe PDF	View/Open